• Consensus Rating: Buy
  • Consensus Price Target: $27.50
  • Forecasted Upside: 53.89%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.87
▼ -0.76 (-4.08%)

This chart shows the closing price for PETQ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PetIQ Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PETQ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PETQ

Analyst Price Target is $27.50
▲ +53.89% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PetIQ in the last 3 months. The average price target is $27.50, with a high forecast of $30.00 and a low forecast of $22.00. The average price target represents a 53.89% upside from the last price of $17.87.

This chart shows the closing price for PETQ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in PetIQ. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/19/2023Jefferies Financial GroupInitiated CoverageBuy$22.00Low
10/2/2023Truist FinancialBoost TargetBuy ➝ Buy$25.00 ➝ $30.00Low
9/6/2023Lake Street CapitalInitiated CoverageBuy$28.00Low
8/15/2023BenchmarkReiterated RatingBuy ➝ Buy$30.00Low
8/9/2023Truist FinancialBoost Target$20.00 ➝ $25.00Low
2/17/2023Truist FinancialLower Target$30.00 ➝ $20.00Low
2/13/2023BenchmarkReiterated RatingBuy$30.00Low
10/25/2022Raymond JamesLower TargetOutperform$21.00 ➝ $16.00Low
9/21/2022Jefferies Financial GroupLower Target$21.00Low
8/10/2022Raymond JamesLower Target$29.00 ➝ $21.00Low
5/13/2022OppenheimerDowngradeOutperform ➝ Market PerformHigh
3/22/2022Truist FinancialLower Target$35.00 ➝ $30.00High
3/3/2022Raymond JamesLower TargetOutperform$32.00 ➝ $29.00High
11/30/2021BenchmarkInitiated CoverageBuy$30.00High
11/4/2021Raymond JamesLower TargetOutperform$41.00 ➝ $32.00High
9/8/2021Jefferies Financial GroupLower TargetBuy$40.00 ➝ $36.00Low
2/26/2021Raymond JamesBoost TargetOutperform$35.00 ➝ $45.00High
11/9/2020OppenheimerReiterated RatingBuy$50.00Low
11/6/2020Raymond JamesLower TargetOutperform$43.00 ➝ $35.00High
8/17/2020GuggenheimBoost Target$130.00 ➝ $175.00Low
8/14/2020Raymond JamesLower TargetOutperform$44.00 ➝ $43.00Low
8/7/2020OppenheimerReiterated RatingBuy$50.00High
8/7/2020Raymond JamesBoost TargetOutperform$41.00 ➝ $44.00High
7/20/2020SunTrust BanksBoost TargetBuy$35.00 ➝ $45.00Low
7/1/2020Raymond JamesBoost TargetOutperform$35.00 ➝ $41.00Low
6/25/2020GuggenheimBoost TargetBuy$33.50 ➝ $44.00Medium
6/16/2020Raymond JamesBoost TargetOutperform$32.00 ➝ $35.00Medium
5/8/2020Raymond JamesLower TargetOutperform$33.00 ➝ $32.00High
5/8/2020SunTrust BanksBoost TargetBuy$30.00 ➝ $35.00High
5/8/2020OppenheimerReiterated RatingBuyHigh
3/11/2020SunTrust BanksReiterated RatingBuy$45.00High
3/11/2020Raymond JamesLower TargetOutperform$40.00 ➝ $38.00High
12/4/2019Raymond JamesReiterated RatingBuyLow
5/23/2019GuggenheimInitiated CoverageBuy ➝ Buy$35.00Medium
3/4/2019Raymond JamesLower TargetOutperform ➝ Outperform$42.00 ➝ $39.00High
(Data available from 2/22/2019 forward)

News Sentiment Rating

1.23 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2023
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/23/2023
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/23/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2024

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
PetIQ logo
PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Read More

Today's Range

Now: $17.87
Low: $17.83
High: $18.78

50 Day Range

MA: $18.54
Low: $17.31
High: $20.00

52 Week Range

Now: $17.87
Low: $9.08
High: $22.98

Volume

195,280 shs

Average Volume

244,108 shs

Market Capitalization

$525.91 million

P/E Ratio

42.55

Dividend Yield

N/A

Beta

1.66

Frequently Asked Questions

What sell-side analysts currently cover shares of PetIQ?

The following sell-side analysts have issued research reports on PetIQ in the last twelve months: Benchmark Co., Jefferies Financial Group Inc., Lake Street Capital, TheStreet, and Truist Financial Co..
View the latest analyst ratings for PETQ.

What is the current price target for PetIQ?

4 Wall Street analysts have set twelve-month price targets for PetIQ in the last year. Their average twelve-month price target is $27.50, suggesting a possible upside of 52.4%. Truist Financial Co. has the highest price target set, predicting PETQ will reach $30.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $22.00 for PetIQ in the next year.
View the latest price targets for PETQ.

What is the current consensus analyst rating for PetIQ?

PetIQ currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PETQ will outperform the market and that investors should add to their positions of PetIQ.
View the latest ratings for PETQ.

What other companies compete with PetIQ?

How do I contact PetIQ's investor relations team?

PetIQ's physical mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company's listed phone number is (208) 939-8900 and its investor relations email address is [email protected]. The official website for PetIQ is www.petiq.com. Learn More about contacing PetIQ investor relations.